fluorouracil has been researched along with veliparib in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Erlichman, C; Geng, L; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Patel, AG; Wagner, JM | 1 |
El-Rayes, B; Gao, H; Landry, J; Shelton, JW; Shu, HK; Wang, L; Waxweiler, TV; Xu, Y | 1 |
Bailey, P; Biankin, AV; Brody, JR; Chang, DK; Laheru, D; Pishvaian, MJ; Wolfgang, CL | 1 |
Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH | 1 |
Brody, JR; He, AR; Hwang, JJ; Kim, SS; Marshall, JL; Pishvaian, MJ; Smaglo, BG; Wang, H; Weinberg, BA; Weiner, LM | 1 |
2 trial(s) available for fluorouracil and veliparib
Article | Year |
---|---|
A phase 2 randomised study of veliparib plus FOLFIRIĀ±bevacizumab versus placebo plus FOLFIRIĀ±bevacizumab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival | 2019 |
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Dose-Response Relationship, Drug; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin | 2020 |
4 other study(ies) available for fluorouracil and veliparib
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Repair; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Female; Floxuridine; Fluorouracil; Humans; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Transfection; Tumor Suppressor Proteins; X-ray Repair Cross Complementing Protein 1 | 2011 |
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Comet Assay; DNA Damage; Female; Fluorouracil; HCT116 Cells; Histones; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis | 2017 |